Otsuka Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President: Taro Iwamoto, Ph. D) is pleased to announce that it has been selected by the Ministry of Economy, Trade and Industry (METI) as a model enterprise for business continuity management. Our continuing efforts on business continuity management (BCM) and strategic use of ISO22301, the international standard for business continuity management, have been awarded for creating a progressive and effective approach that will become a model to the industry and supply chain.

Otsuka is well prepared to quickly recover and continue the manufacturing and supply of all our pharmaceutical products and Nutraceuticals products in the event of a disaster, with the first priority being recovery of business processes related to delivering vital pharmaceutical products. Otsuka is committed to ensuring the stable supply and distribution of pharmaceutical products and Nutraceuticals products that our society needs even when disaster strikes by ensuring preparedness for dealing with business interruptions.

Our business continuity management program entitled "The Manufacturing and Stable Supply of Products for Medical Related Business" was awarded ISO22031 on August 24, 2012 becoming the first and only pharmaceutical company to be certified in Japan. We plan to enhance the scope of the certification including Nutraceuticals products in order to improve our resiliency and capability to continue operating during unexpected events.